Acute medical problems due to Ecstasy use

Swiss Medical Weekly

Volumn 135, Issue 43-44, 2005, Pages 652-657

  Liechti, Matthias E ^a,c   Kunz, Isabelle ^a   Kupferschmidt, Hugo ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Schweizerisches Toxikologisches Informationszentrum   (Switzerland)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Drug abuse; Ecstasy; Intoxication; MDMA

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ALCOHOL; AMPHETAMINE DERIVATIVE; BENZODIAZEPINE; CANNABIS; ILLICIT DRUG; KETAMINE; LYSERGIDE; OPIATE;

ACUTE DISEASE; ADOLESCENT; ADULT; ALCOHOL ABUSE; ANXIETY; ARTICLE; COCAINE DEPENDENCE; COLLAPSE; COMA; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DRUG ABUSE; DRUG INTOXICATION; EMERGENCY TREATMENT; FEMALE; GLASGOW COMA SCALE; HEART ARREST; HEART PALPITATION; HUMAN; HYPERTHERMIA; KIDNEY FAILURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PANIC; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SEIZURE; SUBSTANCE ABUSE; UNCONSCIOUSNESS;

EID: 29144524320     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Baggott M, Smart R, Jerome L. Medical emergencies and adverse events in ecstasy users. 3,4-Methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature: Multidiscipliary Association for Psychodelic Studies 2001:147-85. (www.maps.org/mdma/protocol/mdmareview. pdf)
2. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992;340:384-7.
3. Hartung TK, Schofield E, Short AI, Parr MJA, Henry JA. Hyponatriaemic states following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") ingestion. Q J Med 2002;95:431-7.
4. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4- methylenedioxymethamphetamine ("Ecstasy"). Br J Psychiatry 1994;165:391-5.
5. Cregg MT, Tracey JA. Ecstasy abuse in Ireland. Ir Med J 1993;86:118-20.
6. Rella JG, Nelson LS, Hoffman RS. 7 years of 3,4- methylenedioxymethamphetamine (MDMA) toxicity. Int J Med Toxicol 2000;3:28.
7. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 2001;154:161-8.
8. Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A, "Saturday night fever": ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 1998;15:322.
9. Sanjurjo E, Nogué S, Miró O, Munné P. Analysis of patients attended in an emergency department due to ecstasy consumption. Med Clin (Barc) 2004;123:90-2.
10. Winstock AR, Griffiths P, Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001;64:9-17.
11. Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999;55:105-15.
12. Verheyden SL, Henry JA, Curran HV Acute, sub-acute and long-term subjective consequences of "ecstasy" (MDMA) consumpion in 430 regular users. Hum Psychopharmacol Clin Exp 2003;18:507-17.
13. Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004;134:534-7.
14. Hernandez-Lopez C, Farre M, Roset PN, et al. 3,4- Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 2002;300:236-44.
15. Rodriguez Arenas MA, Barrio Anta G, de la Fuente de Hoz L, Roxuela L. Emergencies associated with the consumption of design drugs, hallucinogens and amphetamines attended at fifteen spanisch hospitals during 1994. Rev Clin Esp 1997;197:804-9.
16. Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000;23:396-404.
17. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ("Ecstasy") induces vasopressin secretion. Lancet 1998;351:1784.
18. Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M. Tödliches Hirnödem nach Einnahme von Ecstasy und Benzylpiperazin. Dtsch Med Wschr 2001;126:809-11.